NO2964A - Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse - Google Patents

Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse

Info

Publication number
NO2964A
NO2964A NO20002964A NO20002964A NO2964A NO 2964 A NO2964 A NO 2964A NO 20002964 A NO20002964 A NO 20002964A NO 20002964 A NO20002964 A NO 20002964A NO 2964 A NO2964 A NO 2964A
Authority
NO
Norway
Prior art keywords
glucose tolerance
impaired glucose
medicament
manufacture
treatment
Prior art date
Application number
NO20002964A
Other languages
English (en)
Other versions
NO314747B1 (no
NO20002964D0 (no
Inventor
Jerrold M Olefsky
Tammy Antonucci
Dean Lockwood
Rebecca Norris
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08293899 external-priority patent/US5478852C1/en
Publication of NO2964A publication Critical patent/NO2964A/no
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20002964D0 publication Critical patent/NO20002964D0/no
Publication of NO314747B1 publication Critical patent/NO314747B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20002964A 1993-09-15 2000-06-09 Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse NO314747B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12225193A 1993-09-15 1993-09-15
US08293899 US5478852C1 (en) 1993-09-15 1994-08-23 Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
PCT/US1994/010389 WO1995007694A1 (en) 1993-09-15 1994-09-14 Use of thiazolidinediones to prevent or delay onset of niddm

Publications (3)

Publication Number Publication Date
NO2964A true NO2964A (no) 1996-05-14
NO20002964D0 NO20002964D0 (no) 2000-06-09
NO314747B1 NO314747B1 (no) 2003-05-19

Family

ID=26820333

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19961041A NO310097B1 (no) 1993-09-15 1996-03-14 Anvendelse av tiazolidindioner for fremstilling av et medikament for å forhindre eller forsinke starten av NIDDM
NO20002964A NO314747B1 (no) 1993-09-15 2000-06-09 Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse
NO20002963A NO314748B1 (no) 1993-09-15 2000-06-09 Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikamentfor behandling av svekket glukosetoleranse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19961041A NO310097B1 (no) 1993-09-15 1996-03-14 Anvendelse av tiazolidindioner for fremstilling av et medikament for å forhindre eller forsinke starten av NIDDM

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20002963A NO314748B1 (no) 1993-09-15 2000-06-09 Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikamentfor behandling av svekket glukosetoleranse

Country Status (16)

Country Link
EP (2) EP1714652A3 (no)
JP (3) JP3081245B2 (no)
CN (3) CN1103590C (no)
AT (1) ATE376829T1 (no)
AU (3) AU679572B2 (no)
CA (1) CA2171827C (no)
CZ (1) CZ283339B6 (no)
DK (1) DK0719140T3 (no)
ES (1) ES2296288T3 (no)
FI (1) FI961213A (no)
HK (1) HK1011925A1 (no)
HU (1) HU228260B1 (no)
NO (3) NO310097B1 (no)
NZ (1) NZ274346A (no)
RU (1) RU2195282C2 (no)
WO (1) WO1995007694A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
JP2000511883A (ja) * 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1998020871A1 (fr) * 1996-11-08 1998-05-22 Nippon Chemiphar Co., Ltd. Agent diminuant la graisse viscerale
AU754479B2 (en) * 1997-05-15 2002-11-14 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US6531461B1 (en) * 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
UA86015C2 (ru) * 2003-01-29 2009-03-25 Такеда Фармасьютикал Компани Лимитед Способ получения твердой лекарственной формы с покрытием
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
NZ541749A (en) 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
FR2858321B1 (fr) * 2003-07-28 2006-01-20 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
AU2007227581B2 (en) * 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP2826379B2 (ja) * 1990-01-22 1998-11-18 三共株式会社 チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
CA2111096C (en) * 1991-06-25 1997-01-14 Steven Wayne Goldstein Thiazolidinedione hypoglycemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
JP2000273043A (ja) 2000-10-03
CZ79396A3 (en) 1996-10-16
JPH09502727A (ja) 1997-03-18
FI961213A (fi) 1996-05-14
HUT75874A (en) 1997-05-28
AU7835194A (en) 1995-04-03
NO310097B1 (no) 2001-05-21
NO314747B1 (no) 2003-05-19
AU679572B2 (en) 1997-07-03
CN1202823C (zh) 2005-05-25
CN1387849A (zh) 2003-01-01
JP2000239167A (ja) 2000-09-05
NZ274346A (en) 1997-06-24
RU2195282C2 (ru) 2002-12-27
DK0719140T3 (da) 2008-03-03
EP0719140B1 (en) 2007-10-31
CN1387848A (zh) 2003-01-01
NO314748B1 (no) 2003-05-19
CZ283339B6 (cs) 1998-03-18
JP3081245B2 (ja) 2000-08-28
NO961041D0 (no) 1996-03-14
ATE376829T1 (de) 2007-11-15
AU1771097A (en) 1997-05-29
WO1995007694A1 (en) 1995-03-23
CN1202821C (zh) 2005-05-25
HK1011925A1 (en) 1999-07-23
NO961041L (no) 1996-05-14
NO2963A (no) 1996-05-14
FI961213A0 (fi) 1996-03-15
CA2171827A1 (en) 1995-03-23
EP1714652A2 (en) 2006-10-25
EP0719140A1 (en) 1996-07-03
NO20002964D0 (no) 2000-06-09
AU1770997A (en) 1997-05-29
EP1714652A3 (en) 2007-01-17
CN1134669A (zh) 1996-10-30
HU9600653D0 (en) 1996-05-28
ES2296288T3 (es) 2008-04-16
AU706947B2 (en) 1999-07-01
EP0719140A4 (en) 2001-08-16
CN1103590C (zh) 2003-03-26
NO20002963D0 (no) 2000-06-09
CA2171827C (en) 2004-06-29
HU228260B1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
NO2964A (no) Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse
WO1995007697A3 (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PL348773A1 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
BR9810172A (pt) Tratamento de diabete com tiazolidinadiona e metformina
CA2071629A1 (en) Use of insulin sensitizing agents to treat hypertension
HU9203837D0 (en) Method for producing oxa-dione and thiazolidin-dione compounds reducing sugar and cholesterol levels of blood
CA2179584A1 (en) Pharmaceutical composition containing insulin sensitivity enhancer in combination with another antidiabetic
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
NO940506L (no)
AU8107694A (en) Use of substituted thiazolidine derivatives in the treatment of raised intraocular pressure
AU2158688A (en) Use of bezafibrate for treating diabetes
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
CS38584A2 (en) Zpusob pripravy 5 (2 alkoxyfenyl) thiazolidindionu
ES2085665T3 (es) Agente neuroprotector.
AU3881889A (en) Human interferon-gamma, process to prepare said human interferon-gamma, and its use
UA8036A1 (uk) Спосіб одержання похідних тіазолу або їх кислотно-аддітивних солей
AU553719B2 (en) Spiro-imidazolones for the treatment of diabetic complications
AU636488C (en) Use of a 1-2(-naphthylethyl)-4-(3-trifluoromethylphenyl)-1, 2,3,6-tetrahydropyridine for the treatment of cerebral and n euronal diseases
UA10248A (uk) Спосіб лікування ішемічної хвороби серця на фоні цукрового діабету

Legal Events

Date Code Title Description
MK1K Patent expired